ONYX PHARMACEUTICALS INC 4

Accession 0001181431-13-052505

CIK 0001012140operating

View on SEC.gov Company Profile

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 8:52 PM ET

Size

31.1 KB

Accession

0001181431-13-052505

Insider Transaction Report

Form 4

Period: 2013-10-01

ONYX PHARMACEUTICALS INCONXX

Lasowski Juergen

SVP, Corporate Development

Transactions

Disposition from Tender
Common Stock
2013-10-01$125.00/sh−1,833$229,125→ 30,250 total
Disposition to Issuer
Stock Options
2013-10-01−38,548→ 0 total
Exercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (38,548 underlying)
Disposition to Issuer
Stock Options
2013-10-01−925→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (925 underlying)
Disposition to Issuer
Stock Options
2013-10-01−37,575→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (37,575 underlying)
Disposition to Issuer
Stock Options
2013-10-01−2,500→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (2,500 underlying)
Disposition to Issuer
Stock Options
2013-10-01−2,653→ 0 total
Exercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (2,653 underlying)
Disposition to Issuer
Stock Options
2013-10-01−43,247→ 0 total
Exercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (43,247 underlying)
Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−30,250$3,781,250→ 0 total
Disposition to Issuer
Stock Options
2013-10-01−37,500→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-30→ Common Stock (37,500 underlying)
Disposition to Issuer
Stock Options
2013-10-01−11,212→ 0 total
Exercise: $35.67From: 2009-05-19Exp: 2018-05-19→ Common Stock (11,212 underlying)
Disposition to Issuer
Stock Options
2013-10-01−72,788→ 0 total
Exercise: $35.67From: 2009-05-19Exp: 2018-05-19→ Common Stock (72,788 underlying)
Disposition to Issuer
Stock Options
2013-10-01−2,625→ 0 total
Exercise: $28.55From: 2010-03-31Exp: 2019-03-31→ Common Stock (2,625 underlying)
Disposition to Issuer
Stock Options
2013-10-01−3,452→ 0 total
Exercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (3,452 underlying)
Disposition to Issuer
Stock Options
2013-10-01−20,100→ 0 total
Exercise: $88.86From: 2014-03-28Exp: 2023-03-28→ Common Stock (20,100 underlying)

Footnotes (2)

[F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Reflects the forfeiture of 8,575 performance based restricted stock units.
[F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.

Documents

1 file

4
rrd392201.xmlPrimary
FORM 4

Issuer

ONYX PHARMACEUTICALS INC

CIK 0001012140

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001012140

Filing Metadata

Form type: 4
Filed: Oct 2, 8:00 PM ET
Accepted: Oct 3, 8:52 PM ET
Size: 31.1 KB

View on SEC.gov